Breaking News
Werewolves of London
Community Through Commerce and Conference – #SolutionsWatch
Israel's Days Are Numbered
Compasses, not maps: China is building a different type of AI
Top Tech News
Our Diesel-Electric Truck Is So Quiet the Military Wants One
World's first hotel entirely staffed by robots to open in 2027
Researchers in China are ignoring bug spray, citronella, and netting.
Our bodies may be able to regrow lost limbs after all
Chinese cars go blacker than black via hybrid nano tech
World first: Human embryo model grows its own organs – in the lab
Dead lithium batteries revived to 95% capacity via electrochemical bath
Compact laser engraver levels up your DIY crafts setup
'Groundbreaking' Potential Lupus Cure Sends Patients into Remission, Allowing Dreams...
SpaceX Orbital Travel and Orbital Hotels Need Starfall – Getting Back Safe and Cheap is Exciting
Single gene therapy injection surprisingly boosts vision in both eyes
Researchers have been left surprised by the effectiveness of an experimental form of this treatment, which involved an injection into one eyeball yet improved vision across both.
Gene therapies have the potential to treat all kinds of health conditions, ranging from cancer, to diabetes in dogs, to obesity and damaged spinal cords. One area where we're seeing some really exciting progress is in hereditary vision loss, with studies demonstrating the potential of gene therapy to treat color blindness, progressive retinal diseases and glaucoma, with some recently receiving approval from the FDA.
Researchers have been left surprised by the effectiveness of an experimental form of this treatment, which involved an injection into one eyeball yet improved vision across both.
Gene therapies have the potential to treat all kinds of health conditions, ranging from cancer, to diabetes in dogs, to obesity and damaged spinal cords. One area where we're seeing some really exciting progress is in hereditary vision loss, with studies demonstrating the potential of gene therapy to treat color blindness, progressive retinal diseases and glaucoma, with some recently receiving approval from the FDA.